1. Home
  2. MAIA vs GNSS Comparison

MAIA vs GNSS Comparison

Compare MAIA & GNSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.17

Market Cap

79.0M

Sector

Health Care

ML Signal

N/A

Logo Genasys Inc.

GNSS

Genasys Inc.

N/A

Current Price

$1.41

Market Cap

77.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
MAIA
GNSS
Founded
2018
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Consumer Electronics/Appliances
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
79.0M
77.0M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
MAIA
GNSS
Price
$1.17
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.87
AVG Volume (30 Days)
★ 624.5K
61.7K
Earning Date
11-06-2026
08-13-2026
Dividend Yield
N/A
N/A
EPS Growth
33.33
★ 44.44
EPS
N/A
★ N/A
Revenue
N/A
★ $26,306,790.00
Revenue This Year
N/A
$39.82
Revenue Next Year
N/A
$12.95
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 29.50
52 Week Low
$0.87
$1.40
52 Week High
$3.19
$2.47

Technical Indicators

Market Signals
Indicator
MAIA
GNSS
Relative Strength Index (RSI) 36.03 39.96
Support Level N/A $1.40
Resistance Level $1.48 $1.60
Average True Range (ATR) 0.08 0.07
MACD -0.02 0.00
Stochastic Oscillator 9.68 11.76

Price Performance

Historical Comparison
MAIA
GNSS

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

About GNSS Genasys Inc.

Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.

Share on Social Networks: